Karmanos Cancer Institute Records Historic Patient Growth in 2025

The institute’s growth trajectory follows a series of multi-million-dollar investments aimed at decentralizing care. Since 2020, Karmanos has added nearly 128,000 square feet of clinical space, establishing new outpatient centers in Dearborn and Roseville while expanding operations in cities like Flint and Lansing. This physical footprint now spans 17 locations, attracting patients from 39 states and several countries seeking specialized expertise.

Beyond facility expansion, the center has prioritized high-stakes clinical research to distinguish its service offerings. With an annual research budget exceeding $60 million, the organization has launched 609 clinical trials since 2020, enrolling over 2,700 patients. These efforts are bolstered by the recruitment of 43 prominent scientists and clinicians, including Dr. Boris Pasche and Dr. Azeddine Atfi, who lead multidisciplinary teams focused on complex cases such as liver and pancreatic cancers.

Technological integration remains central to the institute's patient strategy. Karmanos was the first facility globally to deploy the TheraBionic P-1 device for liver cancer and the first in Michigan to offer Lifileucel immunotherapy for metastatic melanoma. These advancements, paired with high CMS ratings for patient experience and nurse communication, have allowed the institute to maintain quality metrics even as patient volume hits record levels. Leadership now looks to sustain this momentum by bridging the gap between bench-side innovation and community-based access.